

Celgene Corporation

[View the current Celgene Corporation Page on BioPortfolio.com](http://www.bioportfolio.com/biocorporate/466-Celgene+Corporation.html)

(<http://www.bioportfolio.com/biocorporate/466-Celgene+Corporation.html>)

Contact Details:

86 Morris Avenue

Summit

NJ

07901

United States of America

Tel: 1-908-673-9000

Fax: 908 271 4184

Email:

Celgene is a pharmaceutical company with a major focus on the discovery, development and commercialization of small molecules for cancer and immunological diseases. Celgene's medical research and development team is working to extend the boundaries in the areas of small molecule immunotherapeutic and biocatalytic chiral chemistry by developing both new pharmaceuticals and chirally pure versions of existing drugs. Celgene's agrochemical unit, Celgro, is dedicated to the development of chirally pure crop protection agents.

Our goal is to provide hope and ease suffering through the discovery and development of products for therapies for patients with severe and difficult to treat diseases.

Recent Publications by Celgene Corporation:



- [Survival Effect of Venous Thromboembolism in Patients With Multiple Myeloma Treated With Lenalidomide and High-Dose Dexamethasone.](#)

PURPOSE: We conducted a retrospective analysis of the survival effect of...11th November, 2009
Division of Hematology, Blood/Marrow Transplant and Myeloma Program,- J Clin Oncol. 2009 Nov 9. ([DOI Direct Link](#))

- [Pomalidomide and lenalidomide induce p21 WAF-1 expression in both lymphoma and multiple myeloma through a LSD1-mediated epigenetic mechanism.](#)

*Lenalidomide and pomalidomide have both been evaluated clinically for...*8th October, 2009
Celgene, San Diego, California 92121, USA.- Cancer Res. 2009 Sep 15;69(18):7347-56. Epub 2009 Sep 8. ([DOI Direct Link](#))

- [Multicenter, Phase I, Dose-Escalation Trial of Lenalidomide Plus Bortezomib for Relapsed and Relapsed/Refractory Multiple Myeloma.](#)

PURPOSE: Lenalidomide and bortezomib are active in relapsed and...30th September, 2009

Department of Medical Oncology, Dana-Farber Cancer Institute; and Beth- J Clin Oncol. 2009 Nov 9. ([DOI Direct Link](#))

- [Determination of the residual ethanol in hydroalcoholic sealed hard gelatin capsules by static headspace gas chromatography with immiscible binary solvents.](#)
*Static headspace gas chromatography (HS-GC) with immiscible binary...*11th September, 2009
Analytical Research and Development, Celgene Corporation, Summit, NJ- J Chromatogr A. 2009 Apr 10;1216(15):3328-36. Epub 2009 Feb 21. ([DOI Direct Link](#))
- [Thalidomide chemotherapy-induced peripheral neuropathy: actual status and new perspectives with thalidomide analogues derivatives.](#)
*IMiDs compounds are a class of analogues of thalidomide, with greater...*20th August, 2009
Medical Department, Celgene S.r.l., Corso Garibaldi 86 - 20121 Milano,- Mini Rev Med Chem. 2009 Jun;9(7):760-8.
- [Immunomodulatory drugs reorganize cytoskeleton by modulating Rho GTPases.](#)
*IMiDs immunomodulatory drugs, including lenalidomide and pomalidomide...*28th July, 2009
Celgene, San Diego, CA 92121, USA.- Blood. 2009 Jul 9;114(2):338-45. Epub 2009 May 5. ([DOI Direct Link](#))
- [Inhibition of protein kinase CK2 expression and activity blocks tumor cell growth.](#)
*Protein kinase CK2 (CK2) is a highly conserved and ubiquitous...*25th July, 2009
Celgene Corporation, 4550 Towne Centre Court, San Diego, CA, 92121, USA,- Mol Cell Biochem. 2009 Jul 21. ([DOI Direct Link](#))
- [The anti-cancer drug lenalidomide inhibits angiogenesis and metastasis via multiple inhibitory effects on endothelial cell function in normoxic and hypoxic conditions.](#)
*Lenalidomide (Revlimid) is approved for the treatment of...*14th July, 2009
Department of Immunotherapeutics, Celgene Corporation, 86 Morris Avenue,- Microvasc Res. 2009 Mar;77(2):78-86. Epub 2008 Sep 4. ([DOI Direct Link](#))
- [Venous thromboembolism in myelodysplastic syndrome patients receiving lenalidomide: results from postmarketing surveillance and data mining techniques.](#)
*BACKGROUND AND OBJECTIVES: Multiple myeloma treatment with...*2nd June, 2009
Global Drug Safety, Celgene Corporation, Summit, New Jersey, USA.- Clin Drug Investig. 2009;29(3):161-71. doi:
- [Drug delivery to the posterior segment of the eye IV: theoretical formulation of a drug delivery system for subconjunctival injection.](#)
*PURPOSE: The aim of the current study was to provide insights on the...*1st May, 2009
Pharmaceutical and Analytical Development, Novartis Pharmaceuticals- J Ocul Pharmacol Ther. 2009 Feb;25(1):29-37. ([DOI Direct Link](#))
- [Discovery of \(S\)-N-\[2-\[1-\(3-ethoxy-4-methoxyphenyl\)-2-methanesulfonylethyl\]-1,3-dioxo-2,3-dihydro-1H-isoindol-4-yl\] acetamide \(apremilast\), a potent and orally active phosphodiesterase 4 and tumor necrosis factor-alpha inhibitor.](#)
*In this communication, we report the discovery of 1S (apremilast), a novel...*21st April, 2009
Drug Discovery Department, Celgene Corporation, 86 Morris Avenue, Summit,- J Med Chem. 2009 Mar 26;52(6):1522-4. ([DOI Direct Link](#))
- [Lenalidomide: in vitro evaluation of the metabolism and assessment of cytochrome P450 inhibition and induction.](#)
*PURPOSE: To assess the potential for drug-drug interactions between...*18th April, 2009
Early Drug Development, Celgene Corporation, Summit, NJ 07901, USA.- Cancer Chemother Pharmacol. 2009 May;63(6):1171-5. Epub 2008 Nov 23. ([DOI Direct Link](#))
- [Are myelodysplastic syndromes and acute myeloid leukemia one disease?](#)
*PURPOSE: To assess the potential for drug-drug interactions between...*28th February, 2009
Celgene Corporation, 86 Morris Avenue, Summit, NJ 07901 USA.- Leuk Res. 2009 Mar;33(3):351-4. Epub 2008 Nov 8. ([DOI Direct Link](#))
- [RevAssist: a comprehensive risk minimization programme for preventing fetal exposure to lenalidomide.](#)
*Lenalidomide (Revlimid) is an immunomodulatory drug and an analogue of...*7th January, 2009
Global Drug Safety, Celgene Corporation, Summit, New Jersey 07901, USA.- Drug Saf.

2008;31(9):743-52.

- [Therapeutics targeting IL-13 for the treatment of pulmonary inflammation and airway remodeling.](#)
Targeting the IL-13 pathway appears to be a viable approach to ameliorate... 17th December, 2008
Celgene- Curr Opin Investig Drugs. 2008 Nov;9(11):1180-4.

Press Releases on Celgene Corporation:

New Science Program Teaches High School Students About Blood and Career Opportunities in the Field of Hematology	23rd November, 2009	American Society of Hematology	WASHINGTON, Nov. 23 /PRNewswire-USNewswire/ -- The American Society of Hematology (ASH) and Scholastic, the global children's publishing, education, and media company, are launching "Explore
DURECT to Present at the 21st Annual Piper Jaffray Health Care Conference	23rd November, 2009	DURECT Corporation	CUPERTINO, Calif., Nov. 23 /PRNewswire-FirstCall/ -- DURECT Corporation (Nasdaq: DRRX) announced today that Matt Hogan, Chief Financial Officer, and Joe Stauffer, Chief Medical Officer, will be
DaVita Launches Minority Bank Initiative with \$1 Million Investment in Industrial Bank of Washington, D.C. to Support Underserved Communities	23rd November, 2009	DaVita Inc.	Partnerships with Minority Banks in Washington D.C., New York City, Los Angeles and Columbia, S.C. Intended to Spur Economic Growth and Revitalization WASHINGTON, Nov. 23 /PRNewswire-USNewswire/ --
Anthem Blue Cross and Blue Shield in Wisconsin Earns NCQA Accreditation Status of Excellent	23rd November, 2009	Anthem Blue Cross Blue Shield in Wisconsin	MILWAUKEE, Nov. 23 /PRNewswire/ -- Anthem Blue Cross and Blue Shield (Anthem) today announced that its Wisconsin plan has earned the accreditation status of Excellent from the National Committee for
Reportlinker Adds India Dental Devices Investment Opportunities, Analysis and Forecasts to 2015	23rd November, 2009	Reportlinker	NEW YORK, Nov. 23 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue. India Dental Devices Investment Opportunities, Analysis and Forecasts to

BioNews Results for Celgene Corporation



- [News and FDA Updates for Celgene \(NASDAQ:CELG\), Genzyme \(Nasdaq:GENZ\)](#)
American Chronicle: Nov 16 2009 12:51AM Matching: celgene
- [Celgene Corporation to Present at the Lazard Capital Markets 6th Annual Healthcare Conference](#)
Pharma Live: Nov 14 2009 10:40PM Matching: celgene
- [Maxygen Buying Back Stock; Analysts Say No Trend Here](#)
BioWorld: Nov 14 2009 6:06AM Matching: celgene
- [More Than 200 Abstracts Evaluating Celgene Products across a Range of Indications to Be Presented at the 51st](#)
Pharma Live: Nov 13 2009 11:11PM Matching: celgene
- [More Than 200 Abstracts Evaluating Celgene Products across a Range of Indications to Be Presented at the 51st](#)
Therapeutics Daily: Nov 12 2009 5:02AM Matching: celgene
- [Generics firms call Big Pharma anticompetitive](#)
FiercePharma: Nov 12 2009 5:52PM Matching: celgene
- [Generic-Drug Makers Protest Supply Limits](#)
Wall Street Journal Online: Nov 12 2009 2:33AM Matching: celgene
- [More Than 200 Abstracts Evaluating Celgene Products across a Range of Indications to Be Presented at the 51st](#)
Genetic Engineering News: Nov 11 2009 1:19PM Matching: celgene
- [Survival Effect of Venous Thromboembolism in Patients With Multiple Myeloma Treated With Lenalidomide and High](#)
Journal of Clinical Oncology: Nov 11 2009 8:39PM Matching: celgene
- [More Than 200 Abstracts Evaluating Celgene \(CELG\) Products across a Range of Indications to Be Presented at th](#)
BioSpace: Nov 11 2009 7:43PM Matching: celgene
- [Cramers 8 Picks for Cancer's Cure](#)
Cafepharm: Nov 9 2009 4:55PM Matching: celgene
- [InterMune Announces Appointments of Senior Leadership to Prepare for Potential Launch of Pirfenidone](#)
Healthcare Sales & Marketing Network: Nov 8 2009 7:33PM Matching: celgene
- [New Options for Treatment of RA and Lupus are Focus of Rheumatology Thought Leader Panel](#)
PR Newswire: Nov 6 2009 7:18PM Matching: celgene
- [New Options for Treatment of RA and Lupus are Focus of Rheumatology Thought Leader Panel](#)
NewsBlaze: Nov 6 2009 3:48PM Matching: celgene
- [InterMune Announces Appointments of Senior Leadership to Prepare for Potential Launch of Pirfenidone](#)
SmartBrief: Nov 5 2009 4:44PM Matching: celgene

Celgene Corporation Clinical Trials:



- [Safety Study of Lenalidomide With and Without Dexamethasone in Japanese Subjects With Previously Treated Multiple Myeloma](#)



Celgene Corporation Patents:

- 6962940- [\(+\)-2-\[1-\(3-Ethoxy-4-methoxyphenyl\)-2-methylsulfonylethyl\]-4-acetylaminisoindoline-1,3-dione: methods of using and compositions thereof](#)
- 7182953- [Methods and compositions for the prevention and treatment of atherosclerosis restenosis and related disorders](#)
- 7189740- [Methods of using 3-\(4-amino-oxo-1,3-dihydro-isoindol-2-yl\)-piperidine-2,6-dione for the treatment and management of myelodysplastic syndromes](#)
- 7208516- [Methods of the treatment of psoriatic arthritis using \(+\)-2-\[1-\(3-ethoxy-4-methoxyphenyl\)-2-methylsulfonylethyl\]-4-acetylaminoi- soindoline-1,3-dione](#)
- 7230012- [Pharmaceutical compositions and dosage forms of thalidomide](#)
- 7244759- [Isoindoline compounds and methods of making and using the same](#)
- 7256210- [7-amido-isoindolyl compounds and methods of their use](#)
- 7276529- [Methods of the treatment or prevention of exercise-induced asthma using \(+\)-2-\[1-\(3-ethoxy-4-methoxyphenyl\)-2-methylsulfonylethyl\]-4-acetylaminoi- soindoline-1,3-dione](#)
- 7312241- [Diphenylethylene compounds and uses thereof](#)
- 7323479- [Methods for treatment and management of brain cancer using 1-oxo-2-\(2,6-dioxopiperidin-3-yl\)-4-methylisoindoline](#)
- 7325355- [Methods for treatment of atherosclerosis using 1,3-dioxo-2-\(2,6-dioxopiperidin-3-yl\)-4-aminoisoindoline](#)
- 7173058- [Fluoroalkoxy-substituted 1,3-dihydro-isoindolyl compounds and their pharmaceutical uses](#)
- 7153867- [Use of nitrogen substituted thalidomide analogs for the treatment of macular degenerator](#)
- 7147626- [Cord blood and placenta collection kit](#)
- 6962997- [Process and intermediates for resolving piperidyl acetamide stereoisomers](#)
- 7005438- [Pharmaceutically active isoindoline derivatives](#)
- 7019030- [Immunotherapeutic agents](#)
- 7034052- [7-Amido-isoindolyl compounds and their pharmaceutical uses](#)
- 7041680- [\(R\) and \(S\) isomers of substituted 2-\(2,6-dioxopiperidin-3-yl\) phthalimides and 1-oxoisoindolines and methods of using the same](#)
- 7081464- [Topical compositions of cyclic amides as immunotherapeutic agents](#)
- 7091353- [Isoindole-imide compounds, compositions, and uses thereof](#)
- 7115631- [Methods for treatment of cognitive and menopausal disorders with D-threo methylphenidate](#)
- 7119106- [Pharmaceutical compositions of 1-oxo-2-\(2,6-dioxopiperidin-3-yl\)-4-aminoisoindoline](#)
- 7141018- [Methods for delivering a drug to a patient while restricting access to the drug by patients for whom the drug may be contraindicated](#)
- 7329761- [Substituted imides](#)
- 7345062- [Substituted acylhydroxamic acids and method of reducing TNF.alpha.levels](#)
- 7468446- [Substituted heterocyclic compounds and uses thereof](#)
- 7470723- [Diphenylethylene compounds and uses thereof](#)
- 7479499- [Methods of using thalidomide in combination with irinotecan](#)
- 7495112- [Isoindoline compounds and methods of making and using the same](#)
- 7504427- [Fluoroalkoxy-substituted 1,3-dihydro-isoindolyl compounds and their pharmaceutical uses](#)
- 7507759- [Methods of using\(+\)-2-\[1-\(3-ethoxy-4methoxyphenyl\)-2-methylsulfonylethyl\]-4-acetylaminisoindoline-1,3,-dione](#)
- 7511072- [7-amido-isoindolyl compounds and methods of its use](#)
- 7524865- [Methods and compositions for treating an ocular neovascular disease](#)

- 7563810- [Methods of using 3-\(4-amino-1-oxo-1,3-dihydroisoindol-2-yl\)-piperidine-2,6-dione for the treatment and management of myeloproliferative diseases](#)
- 7569597- [Isoindoline compounds and methods of their use](#)
- 7468363- [Methods for treatment of cancers using 3-\(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl\)-piperidine-2,6-dione](#)
- 7465800- [Polymorphic forms of 3-\(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl\)-piperidine-2,6-dione](#)
- 7459560- [Processes and intermediates for resolving piperidyl acetamide stereoisomers](#)
- 7354948- [Methods for treatment of chronic uveitis using cyclopropyl-n-{2-\[\(1S\)-1-\(3-ethoxy-4-methoxyphenyl\)-2-\(methylsulfonyl\)ethyl\]-3-oxoisindoline-4-yl}carboxamide](#)
- 7358272- [Methods of using \(+\)-2-\[1-\(3-ethoxy-4-methoxyphenyl\)-2-methylsulfonylethyl\]-4-acetylaminoisoindoline 1,3-dione](#)
- 7393862- [Method using 3-\(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl\)-piperidine-2,6-dione for treatment of certain leukemias](#)
- 7393863- [Methods of using N-{\[2-\(2,6-dioxo\(3-piperidyl\)-1,3-dioxoisindolin-4-yl\)methyl\]cyclopropyl}-carboxamide for the treatment and management of myelodysplastic syndromes](#)
- 7405237- [Isoindoline compounds and methods of their use](#)
- 7427638- [\(+\)-2-\[1-\(3-ethoxy-4-methoxyphenyl\)-2-methylsulfonylethyl\]-4-acetylaminoisoindoline-1,3-dione:., and methods of synthesis and compositions thereof](#)
- 7431944- [Delivery of multiple doses of medications](#)
- 7435726- [Compositions and methods for the treatment of cancer](#)
- 7435745- [Methods and compositions for inhibition of angiogenesis](#)
- 7459466- [Substituted 2-\(2,6-dioxopiperidin-3-yl\)-phthalimides and -1-oxoisindolines and method of reducing TNF.alpha. levels](#)
- 7576104- [Isoindole-imide compounds, compositions, and uses thereof](#)

BioCorporate Profiles - upgrade to a full profile

BioPortfolio's BioCorporate full profiles offers your organization the opportunity to increase internet traffic to your corporate web site and enhance awareness of your business, technology, products and services. BioCorporate profiles are dynamic and are updated weekly with new information sourced from core information resources: publications, clinical trials, patents and global news.

Why you should upgrade your BioPortfolio BioCorporate profile:

- the ability to amend and add information on products and services to your profile using a membership username and password
- the option to add a corporate logo
- the creation of high value URL links back to your organization's website which will improve search engine ranking - resulting in increased site traffic
- the option have your press releases published on BioPortfolio and distributed via our BioNewsCast service
- an enhanced BioCorporate profile will also improve your exposure on BioPortfolio's related service InDepth and GeneDB

The annual cost is \$995.00 for established organizations and \$495.00 for organizations less than 12 months old.

Resources from the [NCBI](#) used in this document, [NCBI's standard disclaimer applies](#).

Nothing in this document should be used in place of personal medical advice from your own qualified medical practitioner. See BioPortfolio.com [User Agreement](#)

Send comments and feedback to:

Peter Barfoot Managing Director, BioPortfolio Ltd.

UK Tel: (+44) 1300 321501

USA Voicemail and Fax: (+1) 415 680 2472

[Peter Barfoot peter.barfoot@bioportfolio.com](mailto:peter.barfoot@bioportfolio.com)

All rights reserved. All other trademarks recognized.

BioPortfolio Limited is registered in England & Wales at Stafford House, 10 Prince of Wales Road, Dorchester, Dorset, DT1 1PW, UK. No.3312883 VAT No. GB 744 6483 10

Copyright 1997-2009 - BioPortfolio Limited.

